On December 2, 2015, Yantai CellZone Medical Diagnostics Center, located in Shandong International Biotechnology Park, passed the audit and verification of Yantai Health and Family Planning Commission and gained the License of Medical Institution, and became the first third party independent medical test laboratory in Yantai.
Independent medical laboratory, also known as the third party medical laboratory, has independent legal entity qualification and serves all kinds of medical organizations. It conducts medical tests and provides significant technical support for “individual treatment” and “precision medicine”, based on resources sharing and intensive management.
Yantai CellZone Medical Diagnostics Center is set up and operated by Yantai CellZone Medical Diagnostics Center Co., Ltd. as an important new business section of Luye Investment Group’s entering the field of “precision medicine”. The Center gained the approval of Yantai Health and Family Planning Commission and started construction in May 2015. At present, it has passed the overall assessment on laboratory design and fitment, hygiene and environmental evaluation, and has set up standard operation system according to ISO15189, reaching advanced level in China in terms of software and hardware and laboratory conditions. The Center has floor area of 3,000m2, and professional instruments and equipments valued more than 10 million Yuan. The Center also has built a team of more than 20 technicians led by senior talents returned from overseas, which guarantees the clinical testing of body fluid, blood, microorganism, clinical chemistry, clinical immunity, serology, molecular genetics, etc. Centering on the important molecular testing, the Center is building three technical platforms, respectively in the aspect of inherited metabolic diseases testing, genetic testing (the next generation gene sequencing), and microorganism molecular detection (quantative PCR detecting), and aims to establish as a first-class third party molecular medicine testing platform of certain influence in the industry.
In addition to the third party technical services, the Center also actively conducts R&D of key technologies. The Center is building a molecular diagnosis reagent R&D Center and pilot test base of international advanced level jointly with Singapore Vela Diagnostics for the R&D of new testing reagent that can be applied to tandem mass spectrum and flight mass spectrum, the next generation sequencer, the new generation PCR (including quantitative PCR and digital PCR), so as t o cut the dependence on imported genetic testing reagent and make efforts to improve China’s core competence in the field of gene sequencing.